Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Ibrutinib and rituximab provides superior PFS and OS compared to FCR for younger patients with previously untreated CLL

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.12.18
Views: 91

Dr Tait Shanafelt - Standford University, Stanford, USA

Dr Tait Shanafelt gives a press conference at ASH 2018 on the findings of the E1912 which show the combination of ibrutinib and rituximab to be superior to FCR chemoimmunotherapy for younger patients with previously untreated CLL.

Watch his interview with ecancer here.

Related videos

follow us

BGICC conference


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation